secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xtant Medical Holdings, Inc. (XTNT)
CIK:        0001453593
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0001641172-25-023109
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xtant Medical Q2 2025 revenue $35.4M (+18% YoY), net income $3.6M, raises FY guidance
--------------------------------------------------------------------------------

- Revenue $35.4M up 18% YoY; gross margin improved to 68.6% from 62.1%.
- Net income $3.6M ($0.02 diluted EPS) vs net loss $3.9M in Q2 2024.
- Adjusted EBITDA $6.9M vs loss of $0.6M; operating cash flow $1.2M vs use of $5.1M.
- FY2025 revenue guidance raised to $131-$135M (prior $127-$131M), growth 11%-15%.
- Announced sale of non-core Coflex/CoFix/OUS assets to Companion Spine for ~$19.2M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1453593/000164117225023109/0001641172-25-023109-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1453593/000164117225023109/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-023109

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer